Pharmaceutical Industry Analysis | Pharmceutical Trends & Analysis

HOME

RSS

Monday, March 22, 2010

SEARCH

BIO AUSTRALIA

BIO CHINA

BIO INDIA

BIO INDONESIA

BIO JAPAN

BIO KOREA

BIO MALAYSIA

BIO NEW ZEALAND

BIO PHILIPPINES

BIO SINGAPORE

BIO TAIWAN

BIO THAILAND

MORE FEATURES

	Big pharma slashes R&D budget: A reason of concern? Nayantara Som

	Pharma companies have announced a major reduction in their R&D budgets in the coming years. What repercussions will it create on the pharma industry? Increasing R&D productivity was the unanimous reason given out by the heads of these companies

	All Eyes on Chinese healthcare market Jan-Willem Eleveld, David Twinberrow John Woo

	The overall compound annual growth rate of the pharmaceutical market (2009-2013), for its part, is projected to be 24%, with the market reaching an estimated $73 billion by 2013

MOST READ FEATURES

	2000 researchers join OSDD to tackle TB bacteria Narayanan Suresh

	The world's first open source drug discovery program, initiated in India has more than 2000 volunteers within 14 months

	After 75 years, US all set to revamp its $ 2.5 trillion healthcare system Narayanan Suresh

	The US Senate has voted on November 22 to open a full-fledged debate on President Barack Obamas most ambitious plan to overhaul the nations healthcare system which will cost more than $ 1.2 tn in the next 10 years

TODAY'S NEWS

	PPD, SRI sign agreement for vax clinical research services

	ABRAXANE meets primary endpoint in phIII trial for advanced NSCLC

	HealthLinx soon to launch OvPlex in Singapore

	Gelcompany first sale of HPE system in Saudi Arabia

	RIKEN researchers trace proteins that help plants keep time

	Biotron ties up with ACLIRES for conducting trial for BIT225

	Advertisement

	Digital Mag
Read on some of the best articles published in 2009 Issue: February, 2010 Current Issue View / Download
	Top Story
India puts bt brinjal on hold

FEATURES

Trends and issues in electronic clinical data management

Over the last 15 years, Internet and eTechnologies have become an integral part of everyday business in most sectors, but have taken time to gain traction in the clinical trials arena

The urgent need for qualified transportation providers in clinical research

According to a recent study conducted by the UK's MHRA, a staggering 43 percent of critical and major product deficiencies are related to ineffective temperature control and monitoring during storage and transportation

Protecting and Policing IPRs in China

China has become a market of importance. To remain globally competitive, businesses cannot afford to ignore China. So, how can businesses that deal with IP tame the Chinese dragon?

OutBound: Japan industry on the move

The future is in innovative R&D and export markets

APAC to surpass Western Europe in APIs

Growth in the Asia Pacific market is being driven primarily by two of its largest markets India and China

Bailing out ailing PSUs in India

There are five top Government owned or public sector (PS) drug companies in IndiaIndian Drugs and Pharmaceuticals Limited (IDPL), Bengal Chemical and Pharmaceuticals Limited (BCPL), Rajasthan Drugs and Pharmaceuticals Limited (RDPL), Karnataka Antib

A perspective on issues, challenges, solutions: Gus Abdallah, MD, Synertec Asia

The issues facing Asian CMOs have existed ever since the early days of contract manufacturing. While a small number of CMOs have recognized the need and have followed through by addressing these issues the majority continue to ignore them

CMOs in India, China to grow at 20 percent: Global market

The GBI Research in its latest research report published in December 2009 says that the global CMO market was valued at $21 bn in 2008. This market grew at around 9.5 percent in 2007 when the market was approximately $19.5 bn

"India and China have distinctive advantages in CMOs business"- Sumanth Kambhamettu, F&S

While selecting between Indian and Chinese companies, the Western companies will look at both countries as each offers distinctive advantages to the big companies

Big pharma slashes R&D budget: A reason of concern?

Pharma companies have announced a major reduction in their R&D budgets in the coming years. What repercussions will it create on the pharma industry? Increasing R&D productivity was the unanimous reason given out by the heads of these companies


	Advertisement



		CyberMedia Network Websites [Voice&Data] [PCQuest] [CIOL] [Dataquest] [Living Digital] [IDC India] [DQ Channels] [The DQweek] [DARE] [CyberMedia Events] [CyberMedia Digital] [Cyber Astro] [CyberMedia India] [Global Services] [BioSpectrum]



		Copyrights are reserved for BioSpectrum ; Designed by : Altered Black